Protara Therapeutics (TARA) Non-Current Assets (2013 - 2026)

Protara Therapeutics (TARA) has reported Non-Current Assets for 14 consecutive years, with $51.9 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Non-Current Assets rose 23.55% year-over-year to $51.9 million; the TTM figure through Mar 2026 stood at $142.7 million (up 104.57% YoY), while the FY2025 annual figure was $50.0 million, up 437.31% from the prior year.
• Non-Current Assets climbed to $51.9 million in Q1 2026 per TARA's latest filing, from $50.0 million in the prior quarter.
• Across five years, Non-Current Assets topped out at $70.6 million in Q1 2022 and bottomed at $9.0 million in Q3 2025.
• Historically, Non-Current Assets has averaged $27.5 million across 5 years, with a median of $11.8 million in 2023.
• Annual changes were most pronounced in 2023 — Non-Current Assets plunged 83.29% — and 2025, when it surged 437.31%.
• Protara Therapeutics' Non-Current Assets stood at $27.1 million in 2022, then plunged by 62.24% to $10.2 million in 2023, then declined by 9.27% to $9.3 million in 2024, then soared by 437.31% to $50.0 million in 2025, then climbed by 3.93% to $51.9 million in 2026.
• Business Quant data shows TARA's Non-Current Assets at $51.9 million in Q1 2026, $50.0 million in Q4 2025, and $9.0 million in Q3 2025.